Regenerative medicine, also known as stem cell therapy, offers a new range of treatment options for patients suffering from neurological disorders. Here we will discuss Stem Cell Therapy for Neurological Disorders.
Neurological conditions often rely on symptom management through medication. However, stem cell therapy has begun to emerge as a new alternative management option for neurological conditions.
How Does Stem Cell Therapy Work?
Stem cells are the only cells in the human body that can differentiate into specialized cells. Stem cells lie dormant throughout the body in bone marrow, fat tissues, and various organs until they’re needed to regenerate lost or damaged tissue.
When stem cells regenerate, they undergo a process called asymmetrical division. In this process, one cell becomes a perfect replica of the stem cell, and the other cell becomes a specialized cell. Stem cells also reproduce rapidly, so they react quickly when called to action.
The new cells work to repair or replace damaged cells, heal wounds, and restore function lost through dead or damaged cells.
What Neurological Disorders Benefit from Stem Cell Therapy?
As regenerative medicine research continues to grow, studies exploring the effects of stem cell therapy on neurological disorders have shown positive results in helping to manage many conditions such as:
Cerebral palsy is a condition that develops before, during, or shortly after birth due to damage to the brain. Symptoms of cerebral palsy in children include poor coordination and underdeveloped reflexes.
In studies, stem cell therapy shows the potential to replace damaged or nonfunctional brain cells in cerebral palsy patients, provide support to the neurons, and reduce scarring in the brain.
Multiple Sclerosis (MS)
Multiple sclerosis is an autoimmune disease in which the immune system attacks the central nervous system and damages the nerve fibers. The damage to the nervous system interrupts the communication between the brain and the rest of the body, causing symptoms like pain, weakness, and vision loss.
Trials exploring stem cell therapy in treating MS resulted in most patients not experiencing a relapse in MS symptoms or brain lesions for five years after their treatment.
Parkinson’s disease is a neurodegenerative condition in which the loss of neurons in an area of the brain stem reduces dopamine production. As a result, patients with Parkinson’s disease can experience problems with movement, muscle control, gait, and balance.
In early studies, stem cell therapies worked to replace the lost neurons, and patients saw a reduction in muscle rigidity and tremors.
While there’s plenty of work needed to understand the most effective methodology and course of treatment, early research on using regenerative medicine to treat neurological disorders points to promising results. If you would like to learn more about stem cell therapy for Neurological disorders, contact a care coordinator today at Stemedix!
Neurodegenerative conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) occur when neuron populations begin to diminish. There is currently no cure for these types of diseases, though clinical trials to explore various treatment options are ongoing. In particular, regenerative medicine, also known as stem cell therapy, is being heavily researched and has shown remarkable progress in controlling these conditions.
Types of Stem Cells
Stem cells serve as the foundation for every tissue and organ throughout the body. They are unspecialized but have the incredible ability to differentiate into virtually any cell type, as well as the power to self-renew.
Neurodegenerative conditions are characterized by neurons that progressively lose their function and structure, and eventually die off. Because stem cells are able to differentiate into multiple cell types, researchers have begun exploring whether they could replace or repair damaged neurons to control the progression of, or potentially even reverse the damage done by, these illnesses. Existing treatment options are limited, but many researchers are optimistic about stem cells’ potential.
Not all stem cells are the same. Here are the various types, some of which show more efficacy as a treatment for neurodegenerative disease than others:
Tissue-specific stem cells: These somewhat specialized stem cells can generate multiple organ-specific cells and are typically located in areas of the body that can self-replenish, such as the skin and blood.
Embryonic stem cells (ESCs): Located in blastocysts, ESCs are especially promising in neurodegenerative applications. Yet, they do pose some risks, including the risk of rejection. Due to their ability to differentiate into neurons, however, they continue to be studied as a potential therapy.
Induced Pluripotent Stem Cells (iPSCs): iPSCs are artificially derived from adult cells and programmed back to pluripotency, thereby allowing for an unlimited source of any cell type. While they are widely used for developing medications and disease modeling, further research must be done to refine the reprogramming process.
Mesenchymal Stem Cells (MSCs): MSCs can differentiate into several types of cells. Their self-renewal capabilities are far-reaching, making them an ideal candidate for therapies involving tissue repair. They may also be leveraged for cell transplantation in the treatment of neurodegenerative diseases.
Neural Stem Cells (NSCs): NSCs are derived from specific areas of the brain and are therefore specialized cells. They, too, are self-renewing and multipotent.
Types of Neurodegenerative Conditions Regenerative Medicine can Help Manage:
While researchers are uncovering new findings on how stem cells can treat neurodegenerative conditions nearly every day, there has already been progress. Here are some of the conditions stem cell therapy has been used to manage:
Parkinson’s Disease (PD): One hallmark characteristic of PD is the decline of dopamine, caused by the destruction of dopamine-producing brain cells. As dopamine decreases, symptoms such as muscle tremors, challenges with movement, and difficulty thinking arise. Now, researchers have found that stem-cell-derived dopaminergic neurons — in particular, those created through ESCs and iPSCs — could hold success in replacing the destroyed brain cells in individuals with PD.
Alzheimer’s Disease: Through the use of stem cell therapy, researchers at Columbia University have refined the protocol for a unique process of converting skin cells into brain cells. This option streamlines the process of creating neurons to replace those which have become damaged by Alzheimer’s disease. In their research, the cells were able to receive signals just as normal neurons would.
ALS: ALS has proven remarkably challenging to study, as there are many potential causes and therapies may therefore only be effective on specific patient populations. Moreover, the motor neurons, which are directly impacted by the condition, couldn’t be acquired in large enough numbers to study. Now, however, Harvard researchers have been able to derive mature cells that can be manipulated back into stem cells from ALS patients, opening up new doors for studying potential therapies to treat the condition.
While there is more ground to cover before stem cell therapy for neurodegenerative conditions can become mainstream, promising research is consistently being published. Moving forward, it’s likely that stem cells will hold the answer to viable management options for these and other challenging conditions.
Neurodegenerative diseases affect over 50 million Americans each year and occur as a result of nerve cells in the brain, peripheral nervous system, and the central nervous system slowly and progressively losing function before eventually dying.
While significant progress has been made in identifying mechanisms and risk factors contributing to the cause and development of these various neurodegenerative diseases, evidence continues to indicate that many of these conditions are influenced by oxidative stress. Research has also shown that antioxidants, the only strategy used to address this mechanism to date, have been demonstrated to be ineffective and, in some instances, even causing additional side effects.
In addition, although progress has been made in the overall understanding and management of several side effects associated with conditions contributing to neurodegeneration and that multifactor intervention introduced at an early stage is believed to be most successful, research has yet to identify a way to slow the progression of these debilitating conditions.
As part of this review, Angeloni et al. provide an analysis of recent literature examining the role of oxidative stress in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS, retinal ganglion cells, and ataxia. The authors also discuss the emerging role of mesenchymal stem cells (MSC) and their potential in fighting oxidative stress and enhancing antioxidant capacity and neurotrophin expression.
Recent literature concludes that oxidative stress has a significant role in each of the neurodegenerative diseases mentioned above. Specifically, oxidative stress has been found to:
Play a fundamental role in Alzheimer’s disease, affecting different pathways involved in AD brain cells.
Have a causal role and also be a result of different pathologies in PD.
Be both a cause and consequence of impaired function related to ALS.
Be a significant cause of damage in a number of ocular neurodegenerative diseases, including diabetic retinopathy, glaucoma, and retina ischemia-reperfusion injury.
Increase ROS production linked to mitochondrial dysfunction in ataxia cell models.
The literature also indicates that MSC therapy can be a promising future management tool for neurodegenerative disease that enhances antioxidant capacity, increases neurotrophin expression, inhibits pro-inflammatory cytokine secretions, and counteracts microglial ROS production.
However, the authors also conclude that while the role of MSCs in counteracting oxidative stress-related neurodegeneration, additional studies demonstrating a more neurodegenerative disease-specific therapeutic MSC strategy for preventing a broad range of previously mentioned disorders are needed.
Accordingly, these future studies will be useful in helping to discover the appropriate numbers of MSCs needed for transplantation, realize optimal timing of transplantation, identify the correct disease stage for transplantation, and better understand the safety, functionality, recovery, and motor and cognitive improvements of various MSCs used in this process.
In neurodegenerative conditions and cases of brain damage such as traumatic brain injury (TBI), the goal of treatment is usually to manage symptoms and prevent or slow the rate of further damage. Yet, ongoing research suggests stem cells could play an important role in creating new neurons, potentially resulting in repair of central nervous system damage and potentially regrow brain tissue. While the science is still in its infancy, there is evidence to suggest stem cell therapy could help to potentially restore lost brain function.
Just until a couple decades ago, scientists were under the impression that the brain and spinal cord could not rebuild themselves once cells were lost. Yet, in the mid-1990s, neuroscientists discovered that the brain could create new neurons in certain circumstances, which arise from neural stem cells. As undifferentiated cells, the stem cells could give rise to many different brain cell types, including neurons, which carry messages throughout the nervous system.
Further research has supported the idea that neurons can regenerate. For instance, in 2003, research was published which showed improvements in paralyzed rats who were exposed to a virus which caused symptoms similar to that of amyotrophic lateral sclerosis (ALS). Mice that had been previously paralyzed were able to regain some mobility after receiving stem cell injections, and the stem cells took on the characteristics of mature motor neurons.
Researchers have also been exploring stem cell therapies to help treat Parkinson’s disease. The goal is to rebuild the central nervous system through stem cell implantation. While levodopa is the go-to treatment to help regulate dopamine levels which are affected in PD, the drug’s efficacy tends to wear off over time, and its side effects increase. Some researchers have investigated the use of fetal stem cell tissue for PD patients, but lack of standardization and challenges in acquiring donor tissue have been barriers to ongoing research efforts.
With that said, stem cells from umbilical cord blood and adult adipose (fat) or bone marrow can also be coaxed to display many protein markers similar to those found in nervous system cells. It’s unclear whether these cells will ultimately be able to give rise to functioning neurons, but researchers continue to make progress.
Ultimately, there is much left to discover when it comes to the potential role of being able to regrow brain tissue and regenerative therapies such as stem cells in neurodegenerative conditions and brain injury. What we’ve already seen is promising, however. As experts continue to develop a deeper understanding of how stem cells and neurons can work together, patients with these challenging conditions will likely continue to benefit from evolving treatment options. If you would like to learn more then contact a care coordinator today!
Neurodegenerative disease is a broad term encompassing a number of chronic, progressive diseases that result in degeneration and or death of neurons; these diseases include Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) and affect over 50 million Americans each year.
Since neurons possess a very limited ability to reproduce and/or replace themselves, any damage to these cells tends to be permanent and contributes to incurable and progressive debilitating conditions affecting physical movement and mental function.
While research has determined that these neurodegenerative diseases are primarily a result of the accumulation of misfolded proteins in the brain, the specific cause of these conditions remains unknown; additionally, the complexity of these conditions often lead to delayed diagnosis, most often a result of the lack of effective and recognizable biomarkers. To date, no preventative treatment for these conditions exist and any current treatment serves to only delay the progression of the disease, most often with poor results.
In this article, Yao et al. explore the viability of using mesenchymal stem cells (MSCs) as cell replacement therapy for treating neurodegenerative diseases. According to the authors, MSCs demonstrated the ability to self-renew and differentiate coupled with their relative ease of collection, isolation, and ability to culture and their immunoregulatory properties make them a promising potential treatment option.
Although the specific therapeutic mechanisms of MSCs in the treatment of neurodegenerative diseases are still being studied, they have shown potential in three specific areas: homing, paracrine, and immunoregulation.
Homing involves MSCs ability to spontaneously migrate to damaged regions of the body, making them a viable therapeutic treatment option – especially as a carrier of therapeutic drugs. It is hypothesized that MCS’s ability to home should allow drugs to be attached and to pass through the blood-brain barrier to be delivered to locations in the CNS and brain that are affected by neurodegenerative diseases.
Paracrine, or paracrine signaling, is a cell’s ability to release hormones that communicate with the cells in its vicinity. MSCs ability to secrete growth factors, cytokines, chemokines, and various enzymes are important aspects of cell migration and immune regulation. Animal studies have demonstrated using MSC-derived exosomes to improve symptoms associated with muscle atrophy translates into a promising clinical treatment strategy for neurodegenerative diseases.
MSCs are undifferentiated precursor stem cells with low immunogenicity. Researchers attribute the immunoregulation of MSCs to their various interactions with T cells, B cells, and natural killer cells. Animal studies have shown that placental-derived MSCs have demonstrated beneficial effects, particularly in mice with AD; researchers hypothesize that this effect is a result of these MSCs inhibiting the release of inflammatory cytokines, preventing cognitive impairments, and increasing the survival rate of neurons and nerve regeneration. These findings have demonstrated the potential for immunosuppressants, in combination with MSCS, to be used in future clinical treatments of neurodegenerative diseases.
After reviewing numerous in vitro and in vivo experiments in animal models, the researchers have confirmed the potential therapeutic benefits of MSCs as well as their safety and effectiveness in a wide variety of therapeutic applications. Additionally, studies have also demonstrated no serious or concerning adverse reactions associated with clinical trials (both human and animal) using MSCs from autologous or allogeneic sources.
However, Yao et al. caution that as therapies using MSCs continue to develop, so too should the process used for preparing MSCs as well as that used for determining ideal method and dose for patients; taking these steps will contribute to a deeper understanding of MSCs potential when used as a therapeutic treatment for neurodegenerative diseases.
Oligodendrocytes are key neural cells responsible for producing myelin sheaths that wrap around neuronal axons in the central nervous system. Considering that thymosin β4’s (Tβ4) ability to promote neurological recovery in a range of neurological diseases has been well established, Chopp & Zhang (2015) propose oligodendrogenesis as the common link by which Tβ4 supports and promotes recovery after neural injury and neurodegenerative disease.
Citing Tβ4’s propensity to alter cellular expression and target multiple molecular pathways involved in neurovascular remodeling and oligodendrogenesis, it warrants further study into Tβ4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases.
Traditional treatment of neurological diseases, including stroke, traumatic brain injury (TBI), and multiple sclerosis have typically focused on the reduction of lesions and produced no effective or beneficial long-term therapeutic outcomes. As a result, new proposals suggest renewed focus on therapeutic efforts designed to facilitate the restorative process present after injury and with specific focus on the enhancement of neurovascular recovery resulting in improved neurological recovery.
Among the many benefits of using Tβ4 in the restorative/regenerative therapeutic process is that, unlike neuroprotection treatments that must be introduced to damaged tissue before irreversible damage occurs, this treatment can be administered several days – even weeks – after injury and still stimulate the naturally-occurring regenerative process that has been demonstrated to be beneficial in treating several conditions, including stroke and TBI.
Specifically, Tβ4 promotes the remodeling and restoration of the CNS/PNS post-injury and has been shown to improve neurological recovery by allowing for improved neurovascular plasticity, neurite outgrowth, myelination of axons, as well as increasing the production and release of trophic factors to further support the remodeling of the nervous system.
Multiple animal models have demonstrated that Tβ4 facilitates the restorative neurological process by simulating oligodendrocytes (OLGs) and specifically OLG progenitor cells (OPCs) in the CNS. It appears that Tβ4 expedited multiple pathways of neurological recovery by stimulating tiny non-coding RNAs known as microRNAs to promote the generation, translation, and differential of OPCs and OLGs.
While these findings are promising, what remains yet unknown is specifically how Tβ4 affects, or perhaps more appropriately, influences, microRNAs to communicate specific neurological restorative and regenerative instructions among various cells. The predominant theory emerging from relevant research is that this process of intercellular communication is created and moderated by tiny lipid particles known as exosomes.
Considering the safety of Tβ4 for use in human trials and the potential for Tβ4 to treat neurological injury and degeneration, future clinical trials focusing on Tβ4’s specific influence on exosomes, and as a therapeutic restorative for neurological treatment and regeneration, is thought to hold promising clinical translation for future treatments of neurological disease and injury.
This website and its contents are not intended to treat, cure, diagnose, or prevent any disease. Stemedix, Inc. shall not be held liable for the medical claims made by patient testimonials or videos. They are not to be viewed as a guarantee for each individual. The efficacy for some products presented have not been confirmed by the Food and Drug Administration (FDA).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.